Stocks › INVA

Innoviva, Inc.

INVA·Nasdaq·United States United States·USD
$18.41
+0.00 (+0.00%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
INVA
Innoviva, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
INVAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of INVA by members of U.S. Congress · 2 on record
All congressional trades →
PoliticianStockTypeFiledTraded
George WhitesidesGeorge WhitesidesHouse · D · CA INVAInnoviva, Inc. · Stock Sale
$250,001 - $500,000
Apr 23, 2025 Mar 25, 2025 Filing ↗
George WhitesidesGeorge WhitesidesHouse · D · CA INVAInnoviva, Inc. · Stock Sale
$50,001 - $100,000
Apr 23, 2025 Mar 24, 2025 Filing ↗

Whale Activity

Position changes in INVA reported for 2026-09-30 by 344 institutional filers
Increased: 108New: 36Held: 37Decreased: 92Closed: 50No prior filing: 21
  • Increased108
  • New36
  • Held37
  • Decreased92
  • Closed50
  • No prior filing21
FilerSharesValueChange
BlackRock, Inc.12.6M$266.4Mincreased
DIMENSIONAL FUND ADVISORS LP4.5M$95.7Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC4.2M$88.6Mdecreased
RENAISSANCE TECHNOLOGIES LLC3.7M$77.4Mdecreased
STATE STREET CORP3.5M$74.2Mincreased
VANGUARD CAPITAL MANAGEMENT LLC3.2M$67.3Mincreased
MILLENNIUM MANAGEMENT LLC2.6M$54.3Mincreased
SYSTEMATIC FINANCIAL MANAGEMENT LP2.1M$43.8Mincreased
GEODE CAPITAL MANAGEMENT, LLC2.1M$43.7Mdecreased
Sarissa Capital Management LP1.9M$40.1Mheld
MORGAN STANLEY1.7M$36.5Mincreased
GOLDMAN SACHS GROUP INC1.6M$34.4Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by INVA insiders, by quarter · Form 4
-2.0M-1.0M01.0M2.0M2025 Q1: -1.6M2025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

265 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Zhen MarianneChief Accounting Officer Tax withholding −1,127 $21.00 $24K Aug 20, 2026 Form 4 ↗
Basso StephenChief Financial Officer Tax withholding −558 $21.00 $12K Aug 20, 2026 Form 4 ↗
Raifeld PavelChief Executive Officer · Director Tax withholding −1,130 $21.00 $24K Aug 20, 2026 Form 4 ↗
Basso StephenChief Financial Officer Tax withholding −559 $22.24 $12K May 20, 2026 Form 4 ↗
Raifeld PavelChief Executive Officer · Director Tax withholding −1,130 $22.24 $25K May 20, 2026 Form 4 ↗
Zhen MarianneChief Accounting Officer Tax withholding −1,127 $22.24 $25K May 20, 2026 Form 4 ↗
Linden JosephineDirector Grant / award +9,461 $0.00 $0 May 18, 2026 Form 4 ↗
Linden JosephineDirector Grant / award +5,733 $0.00 $0 May 18, 2026 Form 4 ↗
Basso StephenChief Financial Officer Grant / award +1,123 $0.00 $0 May 15, 2026 Form 4 ↗
Raifeld PavelChief Executive Officer · Director Grant / award +1,123 $0.00 $0 May 15, 2026 Form 4 ↗
DiPaolo MarkDirector Grant / award +9,786 $0.00 $0 May 4, 2026 Form 4 ↗
Raifeld PavelChief Executive Officer · Director Grant / award +126.6K $0.00 $0 May 4, 2026 Form 4 ↗
Zhen MarianneChief Accounting Officer Grant / award +12.8K $0.00 $0 May 4, 2026 Form 4 ↗
Schlesinger Sarah J.Director Grant / award +9,786 $0.00 $0 May 4, 2026 Form 4 ↗
Basso StephenChief Financial Officer Grant / award +38.0K $0.00 $0 May 4, 2026 Form 4 ↗
Small Derek ADirector Grant / award +9,786 $0.00 $0 May 4, 2026 Form 4 ↗
Haimovitz JulesDirector Grant / award +9,786 $0.00 $0 May 4, 2026 Form 4 ↗
Basso StephenChief Financial Officer Tax withholding −1,244 $23.39 $29K Feb 20, 2026 Form 4 ↗
Raifeld PavelChief Executive Officer · Director Tax withholding −2,986 $23.39 $70K Feb 20, 2026 Form 4 ↗
Zhen MarianneChief Accounting Officer Tax withholding −2,460 $23.39 $58K Feb 20, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding INVA · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Small-Cap ETF
iShares Trust
4.2M$96.0M0.09%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.2M$50.7M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.9M$44.1M0.05%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.6M$36.5M0.02%Jun 30, 2026
VANGUARD SMALL-CAP VALUE INDEX FUND
VANGUARD INDEX FUNDS
1.0M$23.1M0.03%Jun 30, 2026
U.S. SMALL CAP VALUE PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
1.0M$21.1M0.11%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
803.3K$18.2M0.02%Jun 30, 2026
Avantis U.S. Small Cap Value ETF
American Century ETF Trust
847.3K$17.6M0.06%Aug 31, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
825.8K$17.3M0.05%Jul 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
707.3K$16.1M0.11%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list INVA's shares (CUSIP 45781M101), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 11.1M shares15.4%
    Oct 27, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 3.7M shares5.0%
    Jul 31, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Innoviva, Inc. as client

No lobbying filings found naming Innoviva, Inc. as the client.

Government Contracts

Federal awards to Innoviva, Inc. · USAspending

No federal contract awards found for Innoviva, Inc..

U.S. Patents

Recent USPTO applications naming Innoviva, Inc.

No USPTO patent applications found for Innoviva, Inc..

Annual Financials

From INVA's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$411.3M$358.7M$310.5M$331.3M$391.9M
Operating income$163.7M$166.9M$113.9Mn/a$375.1M
Diluted EPS$3.30$0.36$2.20$2.37$2.87
Operating cash flow$196.9M$188.7M$141.1M$201.7M$363.8M
Cash and equivalents$550.9M$305.0M$193.5M$291.0M$201.5M
Total assets$1.64B$1.30B$1.24B$1.23B$926.4M
Shareholders' equity$1.17B$691.2Mn/a$565.8M$414.7M

As Innoviva, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in INVA's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeMay 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 4, 2026
    EDGAR ↗

About Innoviva, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBURLINGAME, CA
IncorporatedDE
Former namesTHERAVANCE INC, ADVANCED MEDICINE INC